With Personalized Pricing, Disclosure Is a Start, But Not a Finish Line
TINA.org and other consumer advocates file comment with FTC.
Fust et al. v. Gilead Sciences, Inc.
23-at-1244, E.D. Cal.
(Sept. 2023)
Remdesivir
Falsely marketing Remdesivir as safe and effective against COVID-19 without disclosing its limitations and adverse events, including fatalities
Pending
TINA.org and other consumer advocates file comment with FTC.
New book explores why MLMs are often associated with harmful outcomes – and what can be done about it.
Marketing and reality are not in sync.
New study opens the floodgates to class-action litigation.
Agency alleges MLM misled recruits about earnings, pressured distributors to buy products and encouraged fake retail sales.